

# Neoadjuvant chemotherapy use up in ovarian cancer treatment

September 12 2016

---



(HealthDay)—For patients with stage IIIC to IV ovarian cancer,

neoadjuvant chemotherapy (NACT) use increased from 2003 to 2012, according to a study published online Sept. 6 in the *Journal of Clinical Oncology*.

Larissa A. Meyer, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues examined the use of NACT versus primary cytoreductive surgery (PCS) in a multi-center observational study. Data were included for 1,538 women with stages IIIC to IV [ovarian cancer](#) who were diagnosed between 2003 and 2012. Overall survival, morbidity, and postoperative residual disease were compared in a propensity-score matched sample of 594 patients.

The researchers found that from 2003-2010 to 2011-2012 there was an increase in NACT use from 16 to 34 percent in stage IIIC disease and from 41 to 62 percent in stage IV disease (both  $P_{\text{trend}}$

"Future studies should prospectively consider the efficacy of NACT by extent of residual disease in unselected patients," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.

**More information:** [Abstract](#)  
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

Citation: Neoadjuvant chemotherapy use up in ovarian cancer treatment (2016, September 12) retrieved 20 March 2024 from <https://medicalxpress.com/news/2016-09-neoadjuvant-chemotherapy-ovarian-cancer-treatment.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private
---

study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.